General Information of the Drug (ID: M6APDG00568)
Name
Erythromycin
Synonyms
A/T/S; Abboticin; Abomacetin; Acneryne; Acnesol; Adecane-2,10-dione (non-preferred name); Ak-Mycin; Akne Cordes Losung; Akne-Mycin; Akne-mycin (TN); Aknederm Ery Gel; Aknemycin; Aknin; AustriaS; Benzamycin; Benzamycin Pak; C-Solve-2; Del-Mycin; Derimer; Deripil; Dotycin; Dumotrycin; E-Base; E-Base (base); E-Glades; E-Mycin; E-Mycin (base); E-Solve 2; E-mycin, Erycin, Robimysin; E0751; ERY; ERYC; ERYC (base); ERYTHROMYCIN STEARATE; Emgel; Emu-V; Emu-Ve; Emuvin; Emycin; Endoeritrin; Erecin; Erimycin-T; Erisone; Eritomicina; Eritrocina; Eritromicina; Eritromicina [INN-Spanish]; Ermycin; Eros; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-Tab (base); Ery-maxin; Eryacne; Eryacnen; Eryc (TN); Eryc 125; Eryc Sprinkles; Eryc-125; Eryc-250; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Erygel (TN); Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythra-Derm; Erythro; Erythro-Statin; Erythro-Teva; Erythroderm; Erythrogran; Erythroguent; Erythromast 36; Erythromid; Erythromycin & VRC3375; Erythromycin (JP15/USP/INN); Erythromycin A; Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Erythromycin Lactate; Erythromycin Ointment; Erythromycin [INN:BAN:JAN]; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Erythromycin, compd. with monododecyl sulfate, sodium salt; Erythromycine; Erythromycine [INN-French]; Erythromycinum; Erythromycinum [INN-Latin]; Erytop; Erytrociclin; Ilocaps; Ilosone (TN); Ilosone (estolate); Iloticina; Ilotycin; Ilotycin T.S; Ilotycin T.S.; Inderm; Inderm Gel; IndermRetcin; Kesso-Mycin; Latotryd; Lederpax; Mephamycin; Mercina; N-Methylerythromycin A; Oftalmolosa Cusi Eritromicina; Oftamolets; PCE Dispertab (base); Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pce (TN); Pharyngocin; Primacine; Propiocine; Proterytrin; R-P Mycin; Retcin; Robimycin; Romycin; Sans-acne; Sansac; Skid Gel E; Staticin; Staticin (TN); Stiemicyn; Stiemycin; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; T-Stat; T-stat (TN); Taimoxin-F; Theramycin Z; Tiloryth; Tiprocin; Torlamicina; Udima Ery Gel; Wemid
    Click to Show/Hide
Status
Approved
Structure
3D MOL
Formula
C37H67NO13
InChI
1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
InChIKey
ULGZDMOVFRHVEP-RWJQBGPGSA-N
PubChem CID
12560
VARIDT Drug ID
DR00050
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Erythromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Erythromycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Erythromycin through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Erythromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [4]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82. doi: 10.1007/s11095-008-9741-x. Epub 2008 Oct 29.